|
Obviously, your knowledge of Cephalon is limited to what is said in the SEC statement. It is advisable, when investing, to research the company in much greater detail then what is said in this statement. Your posts are rather boring and almost meaningless, but I will address them anyway. It appears to me that you are much more interested in me selling my shares than I am in you buying them. Smells like a desperate "short" to me. Fact 1: There are actually 37,451 ALS cases currently reported in the US (as of 9/30/96). You are relying on the SEC report rather than actually finding out for yourself if the figure is correct. Mistake. Rilutek is far from being Myotrophin. It is hardly to be considered as competition to Myotrophin. Please research the effectiveness of Rilutek, I am sure you haven't. Mistake again. There are NO other drugs to treat ALS on the near-term horizon. That is a fact. At this point, it appears that you are counting on Myotrophin to be the major money maker for Cephalon. Third Mistake. Fact 2: PROVIGIL is the ONLY non-amphetamine, non-addictive, virtually side effect free drug EVER for narcolepsy. Now it is in testing for ADD. It will blow away Ritalin. I did not see that ADD trial, which is currently started, on your Cephalon list. Come on, harkenman, do your research! Check out Ritalin information. Then check out Provigil. It is astounding. Incidentally, I do plan to hold on for that 3-7 year period you were talking about. But, being a short, you could never understand that. A stock can tank short term, but if it is up long term, and you hold, you make money. Now, until you post some facts, real facts, not SEC mumbo-jumbo that companies need to file in order to protect themselves from saying they are "touting" their own stock, I won't waste my time responding. You keep repeating yourself. |
